Biotechnology Industry News
Biotechnology industry news, updates, and press releases

Over the past decades, global health has moved from discrete disease campaigns to major developmental strategies. However, medication affordability remains an important, unsolved challenge for industry and the global community. This effort requires coordinated actions by multiple stakeholders. Industry can play a specific role through responsible, differentiated pricing of medicines. Public policies should incentivize such pricing policies rather than discouraging them by external reference pricing or parallel trade. Providing opportunities for industry to invest in emerging markets sustainably, patients will benefit from greater access and support attainment of the UN Millennium Development Goals.

Full details at the Journal of Commercial Biotechnology

There has been a trend of worldwide harmonization of patent laws. Due to the continuing harmonization, examination of patents in Europe and the United States are very similar.  However, examination standards between the two patent offices can differ. Thus, applicants should be aware of the differences between examination standards since both standards need to be addressed in the single patent application.  This paper will review some of these differences, both major and subtle, that should be considered when drafting a biotech patent for filing in both the U.S. and Europe.

Full details at the Journal of Commercial Biotechnology

Recently becoming the sixth largest economy in the world, Brazil has relied, in large part, on its comparative advantages of resource extraction and agriculture. Sustained long-term growth will require Brazil moves into higher value industries that build of off its comparative advantage. Biotechnology has surfaced as a sector of strategic importance, and government involvement in finance, education and research and development has created an industry on the cusp of global significance. By examining sources of finance, human capital accumulation, research and development, intellectual property rights and supporting institutions, we seek to provide a broad overview of Brazil’s nascent biotechnology sector. Spotlights of the agriculture, human health and reagent industries as well as an analysis of the Minas Gerais biotechnology cluster flesh out biotechnology’s place in Brazil’s economy. An antiquated intellectual property rights regime, an insufficient number of qualified researchers and dearth of venture capital firms and private sources of finance are key bottlenecks that must be addressed in order to promote industry growth and consolidation.

Full details at the Journal of Commercial Biotechnology

Assuring a safe and adequate blood supply in developing nations such as emerging markets is a daunting challenge that directly affects fundamental health metrics of a country. Numerous mortalities can be reduced when an effective national blood transfusion system is in place including leading causes of death such as maternal hemorrhage, sickle cell anemia, and malaria. There exists a circular relationship between blood supply and safety: efforts to ensure donor and recipient safety reduce the population of eligible voluntary blood donors, which in turn restricts blood supply. In this article we describe the main issues for blood supply in developing nations and emerging markets, identify the major causes and impact of transfusion transmitted infections, present a safety model that describes the relationship between defensive barriers in depth to assure safe blood, its effectiveness, and the impact it has on safe blood supply. We use twenty two nations in sub-Sahara Africa to present the safety model. Finally, we discuss strategies for blood safety and supply in developing nations.

Full details at the Journal of Commercial Biotechnology